Pubblicazioni

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): And randomised, phase 3, open-label, multicentre study

2016 - THE LANCET ONCOLOGY

Dimopoulos, Meletios A; Moreau, Philippe; Palumbo, Antonio; Joshua, Douglas; Pour, Ludek; HÃ¡jek, Roman; Facon, Thierry; Ludwig, Heinz; Oriol, Albert; Goldschmidt, Hartmut; RosiÃ±ol, Laura; Straub, Jan; Suvorov, Aleksandr; Araujo, Carla; Rimashevskaya, Elena; Pika, Tomas; Gaidano, Gianluca; Weisel, Katja; Goranova Marinova, Vesselina; Schwarer, Anthony; Minuk, Leonard; Masszi, TamÃ¡s; Karamanesht, Ievgenii; Offidani, Massimo; Hungria, Vania; Spencer, Andrew; Orlowski, Robert Z; Gillenwater, Heidi H; Mohamed, Nehal; Feng, Shibao; Chng, Wee Joo; Endeavor, Investigators; Foa, Roberto